NCT06030076Recruiting
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
A Non-interventional, Prospective Cohort, Multicentre, Real-world Evidence Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis in Austria and Switzerland
Source: ClinicalTrials.gov · Last updated 29 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 1 Sept 2023
- Start date
- 6 Sept 2023
- Primary completion date
- Oct 2025
- Lead sponsor
- Almirall, S.A.
- Diseases
- Psoriasis
- NCT number
- NCT06030076
What you commit to
- Study type: Observational
- Planned participants: 50
- From 6 Sept 2023 to the primary completion date, Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \>=3 previous biologic treatments in the last 3 years.
- Previous treatment with Tildrakizumab.
Other illness
- Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance.
Other
- Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the Investigator, should not participate in the study.
- Participation in a clinical trial simultaneous to participation in SW-ATCH.
- Patient dependent on the Investigator.
Who the study is looking for
- Written informed consent.
- \>=18 years of age.
- Moderate-to-severe plaque psoriasis currently treated with a biologic therapy (TNFα antagonist, IL12/23 antagonist, IL17 antagonist).
- Switch to tildrakizumab due to:
- primary or secondary treatment failure (PASI \>= 3 or ΔPASI \< 75 and/or DLQI \> 5)
- adverse events, contraindication, intolerance
- patient wish (dosing regimen), lack of adherence, or other, including nonmedical reason
- Treatment with tildrakizumab planned in the frame of clinical practice.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gesundheitszentrum Citypark Graz Coordinator of this site? Confirm its status | Graz | Austria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.